United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics (UTHR) announced the world's first successful transplant of a UKidney™ into a living person on November 25, 2024. This marks the company's fourth xenotransplant, following two UHeart™ transplants in 2022-2023 and a UThymoKidney™ transplant earlier in 2024. The recipient, 53-year-old Towana Looney from Alabama, received the transplant at NYU Langone Health under FDA's compassionate use pathway.

The UKidney is an investigational xenokidney from a pig with 10 gene edits, developed by UTHR's subsidiary Revivicor. The company is preparing to submit an IND application and plans to start human clinical trials in 2025. UTHR has also inaugurated a clinical-scale pathogen-free facility in Christiansburg, Virginia, with capacity for approximately 125 organs per year, with another facility under construction in Minnesota.

United Therapeutics (UTHR) announced its participation in the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. Patrick Poisson, Executive Vice President of Technical Operations, will present a company update during a fireside chat on Tuesday, November 12, 2024, from 2:45 PM to 3:20 PM PST.

The session will be accessible through a live webcast on the company's website, with a recorded version available for 180 days after the event. United Therapeutics, operating as a public benefit , focuses on developing novel pharmaceutical therapies and technologies to increase transplantable organ availability.

United Therapeutics (UTHR) reported strong Q3 2024 financial results with total revenues growing 23% year-over-year to $748.9 million. Net income increased 16% to $309.1 million, with diluted EPS of $6.39. Tyvaso remained the biggest growth driver, with total revenues up 33% to $433.8 million. The company achieved record revenue for the sixth straight quarter, driven by increasing demand for pulmonary hypertension and high-risk neuroblastoma treatments. The company also expects multiple clinical data reads and regulatory events in 2025.

United Therapeutics (UTHR) and its subsidiary Lung Bioengineering (LBE) announced their 500th lung transplant using centralized ex vivo lung perfusion (EVLP) service. Since 2014, they have evaluated over 800 donated lungs, with the milestone transplant performed at Mayo Clinic in Florida. EVLP technology helps evaluate donor lungs outside the body, increasing the availability of transplantable organs. Currently, only about 20% of donor lungs in the U.S. initially meet transplant standards, with approximately 1,400 people on the waiting list and 300 annual deaths while waiting. LBE operates facilities in Silver Spring, Maryland, and Jacksonville, Florida, serving 25 transplant centers across North America.

United Therapeutics (Nasdaq: UTHR) has announced it will release its third quarter 2024 financial results before market opening on Wednesday, October 30, 2024. The company will issue a detailed press release at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time. The webcast will be accessible through the company's investor relations website and will remain available for replay for one year.

United Therapeutics (Nasdaq: UTHR) announced its participation in the CHEST 2024 Annual Meeting from October 6-9, 2024, in Boston. The company will present five oral presentations and one poster across its commercial and development portfolio. Key highlights include:

1. Data from the BREEZE open-label extension study of Tyvaso DPI®, detailing long-term outcomes and dosing in pulmonary arterial hypertension patients.

2. A sponsored symposium on Tyvaso DPI®: Clinical Pearls and Drug-Device Characteristics.

3. Presentations on patient-reported outcomes, health-related quality of life, and real-world hospitalization differences in pulmonary hypertension patients.

4. Sponsorship of the Women in Chest Medicine Annual Luncheon and the Advanced Practice Providers in Chest Medicine Forum.

United Therapeutics (UTHR) has released its 2024 Corporate Responsibility and Public Benefit Report, highlighting progress towards its public benefit goals in FY 2023. As a public benefit , UTHR focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability. Key achievements include:

- Serving over 14,500 patients, with 100+ benefiting from ex vivo lung perfusion service
- Patient assistance program helping 32,000+ patients access treatments since 2010
- 90%+ employee satisfaction as a Great Place to Work since 2018
- 26% of properties LEED certified, including LEED Platinum Unisphere building
- Maintaining 7-MW capacity onsite solar fields

The company emphasizes balancing patient needs, employee welfare, and environmental sustainability in its operations.

United Therapeutics (Nasdaq: UTHR), a public benefit , has announced its participation in two upcoming investor conferences. Michael Benkowitz, President and COO, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on September 4, 2024. James Edgemond, CFO and Treasurer, will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024.

Both sessions will be accessible via live webcasts on the company's website, with archived recordings available for 90 days. United Therapeutics is known for its innovative approach to addressing unmet medical needs and its unique status as the first publicly-traded biotech or pharmaceutical company to become a public benefit

United Therapeutics (UTHR) reported strong financial results for Q2 2024, with total revenues growing 20% year-over-year to $714.9 million. Key highlights include:

- Net income increased 7% to $278.1 million
- Diluted EPS rose 12% to $5.85
- Tyvaso revenues grew 25% to $398.2 million
- Remodulin revenues increased 16% to $147.3 million

The company attributed its growth to continued traction for Tyvaso in pulmonary hypertension associated with interstitial lung disease, along with strong performance of other products. United Therapeutics also announced a $1 billion accelerated share repurchase program, with final settlement expected in Q3 2024.